Yi Xia

Sun Yat-sen University — China

Medicine · Health Sciences

37h-index4.2kcitations248works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(156), Chronic Lymphocytic Leukemia Research(88), Viral-associated cancers and disorders(61), Immune Cell Function and Interaction(30), CNS Lymphoma Diagnosis and Treatment(23)

Publications248 total

Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer
Scientific Reports·2025Open Access
Clinical characteristics and survival outcomes of thymic mucosa‐associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients
Cancer·2025· 1 citedOpen Access
Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study
Blood·2025Open Access
Balloon Dilation versus Amplatz Dilation in Totally Ultrasound-guided Percutaneous Nephrolithotomy: a retrospective analysis of efficacy and safety
2025Open Access
Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients
Annals of Hematology·2025Open Access
LBA4 Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6)
Annals of Oncology·2025Open Access
Case Report: A rare chromosomal imbalance with dup 7q36.3-qter and del 7pter-p22.3 arising from parental pericentric inversion
Frontiers in Genetics·2025Open Access
814 | FIRST‐LINE SELINEXOR IN COMBINATION WITH R‐CHOP FOR EBV‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (XPLORE): A SINGLE‐ARM, PHASE IB/II Trial
Hematological Oncology·2025Open Access
550 | PHASE II TRIAL OF ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE CWCLL‐001 TRIAL
Hematological Oncology·2025Open Access
Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.
Journal of Clinical Oncology·2025· 1 cited
A Fatty Acid Metabolic Signature for Prognosis (FAMOUS) in Breast Cancer
Preprints.org·2025Open Access
Prognostic impacts of <i>RHOA G17V</i> mutation in cell‐free <scp>DNA</scp> assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T‐cell lymphoma
British Journal of Haematology·2025Open Access
CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia
Leukemia·2025· 3 cited
179TiP: Lorlatinib as neoadjuvant treatment in stage IB-IIIB ALK-rearranged non-small cell lung cancer (NEOLORA)
Journal of Thoracic Oncology·2025Open Access
Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study
Blood·2024
P3.08E.02 An Artificial Intelligence Driven Approach to Predict Pathological Response to Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2024Open Access
Orelabrutinib, rituximab, temozolomide and high-dose methotrexate (RMOT) in newly diagnosed primary central nervous system lymphoma (PCNSL): A retrospective analysis on efficacy and safety.
Journal of Clinical Oncology·2024· 3 cited
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
The Lancet Haematology·2024· 26 cited
174P Intracranial (IC) activity of ivonescimab (ivo) alone or in combination with platinum doublet chemotherapy (PC) in patients (Pts) with advanced non-small cell lung cancer (aNSCLC) and brain metastases (BMs)
ESMO Open·2024· 3 citedOpen Access
[Biological characteristics and clinical significance of stereotyped B-cell receptor in chronic lymphocytic leukemia].
PubMed·2024Open Access
page 1 of 13Next →

Frequent Co-authors

Zhiming Li(14), Ken H. Young(11), Wei Xu(11), Panpan Liu(10), Lei Fan(10), Wen-Qi Jiang(9), L. Jeffrey Medeiros(9), Huayuan Zhu(9), Jianyong Li(9), Peng Sun(8), Hui-Qiang Huang(8), Zijun Y. Xu‐Monette(8), Yu Wang(7), Jin‐Hua Liang(7), Jia-Jia Huang(6), Ganiraju C. Manyam(6), Carlo Visco(6), Jooryung Huh(6), Karen Dybkær(6), Alexandar Tzankov(6)